van de Kerkhof PCM, et al. - Given that psoriasis is a chronic inflammatory skin disease correlated with quality of life (QoL) impairment, researchers sought to examine treatment impact on QoL overall and by patient subgroups categorized by disease severity, as well as analyze week 8 efficacy responses as possible predictors of Week 16 Dermatology Life Quality Index (DLQI) outcomes. For this post hoc analysis, study participants were randomized to receive a maximum daily dose of 720 mg of dimethylfumarate (DMF), fumaric acid esters [FAE] (gradual up-titration) or placebo for 16 weeks. Six hundred seventy-one patients were included in the full analysis set (267 randomized to DMF, 273 to FAE and 131 to placebo) at baseline. The authors discovered that DMF significantly improved outcomes of DLQI compared with placebo and was not affected by the severity of the baseline disease. Responses to efficacy (PASI 50/75, PASI ≤3 and PGA 0-1) as early as Week 8 predicted QoL results in patients treated with DMF and FAE at Week 16.